119023-25-5

Basic information

• Product Name: Benzamide, 2-amino-4-fluoro- (9CI)
• Synonyms: Benzamide, 2-amino-4-fluoro- (9CI);2-Amino-4-fluorobenzamide;4-fluoroanthranilaMide;2-Amino-4-Fluorobenz
• CAS NO: 119023-25-5
• Molecular Formula: C₇H₇FN₂O
• Molecular Weight: 154.1416832
• Product Categories: AMIDE
• Mol File: 119023-25-5.mol
• Article Data: 16

Chemical Properties

• Melting Point: 132 °C(Solv: benzene (71-43-2))
• Boiling Point: 270.807 °C at 760 mmHg
• Flash Point: 117.58 °C
• Appearance: /
• Density: 1.345 g/cm³
• Vapor Pressure: 0.007mmHg at 25°C
• Refractive Index: 1.604
• Storage Temp.: 2-8°C(protect from light)
• PKA: 15.69±0.50(Predicted)
• CAS DataBase Reference: Benzamide, 2-amino-4-fluoro- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Benzamide, 2-amino-4-fluoro- (9CI)(119023-25-5)
• EPA Substance Registry System: Benzamide, 2-amino-4-fluoro- (9CI)(119023-25-5)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 119023-25-5(Hazardous Substances Data)

Usage

General Description

Benzamide, 2-amino-4-fluoro- (9CI) is a chemical compound with the molecular formula C7H7FN2O, usually found as a white powder. It belongs to the Benzamides and its derivatives group of chemicals that have a variety of uses, including in the pharmaceutical industry for the production of drugs. Benzamide, 2-amino-4-fluoro- (9CI) has various applications in organic synthesis due to its unique reactivity. Additionally, it provides the basis for the synthesis of various other compounds. Its toxicity and safety procedures are described in Material Safety Data Sheets and appropriate protective measures should be taken when handling it.

InChI:InChI=1/C7H7FN2O/c8-4-1-2-5(7(10)11)6(9)3-4/h1-3H,9H2,(H2,10,11)

Upstream product

• 106754-80-7 4-fluoro-2-nitrobenzamide 
• 446-32-2 4-fluoroanthranilic acid 
• 394-01-4 4-fluoro-2-nitrobenzoic acid 
• 57750-82-0 4-Fluoro-2-nitrobenzoic acid chloride 
• 940054-57-9 2-amino-4-fluorobenzoic acid cyanomethyl ester 
• 321-50-6 7-fluoro-1H-benzo[d][1,3]oxazine-2,4-dione 

Downstream Products

• 105189-35-3 7-Fluoro-2-[3-(3-piperidin-1-ylmethyl-phenoxy)-propyl]-3H-quinazolin-4-one 
• 157864-21-6 4-fluoro-2-[N-(pyridin-3-ylcarbonyl)amino]benzamide 
• 80517-22-2 2-amino-4-fluorobenzonitrile 
• 733736-89-5 2-aminomethyl-5-fluoro-aniline 
• 1241915-11-6 2-(2-bromo-2-(4-fluorophenyl)acetamido)-4-fluorobenzamide 
• 1241915-15-0 2-(2,2-difluoro-2-(4-fluorophenyl)acetamido)-4-fluorobenzamide 
• 1253731-89-3 2-(4-benzyloxy-3,5-dimethylphenyl)-7-fluoro-3H-quinazolin-4-one 
• 1319212-84-4 2-(4,6-dichloro-[1,3,5]triazin-2-ylamino)-4-fluorobenzamide 
• 1319212-85-5 2-{4,6-bis(isobutylamino)-[1,3,5]triazin-2-ylamino}-4-fluorobenzamide 
• 194473-03-5 7-fluoro-2-methylquinazolin-4(3H)-one 
• 1315337-24-6 7-fluoro-2-phenylquinazolin-4(3Η)-one 
• 321-50-6 7-fluoro-1H-benzo[d][1,3]oxazine-2,4-dione 
• 917343-25-0 2-amino-4-fluoro-N-methylbenzamide 

Relevant articles and documents

Acetylcholinesterase inhibitors for potential use in Alzheimer's disease: Molecular modeling, synthesis and kinetic evaluation of 11H-indeno-[1,2-b]-quinolin-10-ylamine derivatives

Continuing our work on tetracyclic tacrine analogues, we synthesized a series of acetylcholinesterase (AChE) inhibitors of 11H-indeno-[1,2-b]-quinolin-10-ylaminic structure. Selected substituents were placed in synthetically accessible positions of the tetracyclic nucleus, in order to explore the structure-activity relationships (SAR) and the mode of action of this class of anticholinesterases. A molecular modeling investigation of the binding interaction of the lead compound (1a) with the AChE active site was performed, from which it resulted that, despite the rather wide and rigid structure of 1a, there may still be the possibility to introduce some small substituent in some positions of the tetracycle. However, from the examination of the experimental IC50 values, it derived that the indenoquinoline nucleus probably represents the maximum allowable molecular size for rigid compounds binding to AChE. In fact, only a fluorine atom in position 2 maintains the AChE inhibitory potency of the parent compound, and, actually, increases the AChE-selectivity with respect to the butyrylcholinesterase inhibition. By studying the kinetics of AChE inhibition for two representative compounds of the series, it resulted that the lead compound (1a) shows an inhibition of mixed type, binding to both the active and the peripheral sites, while the more sterically hindered analogue 2nScheme 1Reagents: (a) ZnCl2 reflux; (b) (1) benzaldehyde reflux, (2) NaBH4. seems to interact only at the external binding site of the enzyme. This finding seems particularly important in the context of Alzheimer's disease research in the light of recent observations showing that peripheral AChE inhibitors might decrease the aggregating effects of the enzyme on the β-amyloid peptide (βA). Copyright (C) 2000 Elsevier Science Ltd.

COMBINATION THERAPY FOR TREATING MPS1

The application is directed to compounds of formula (I) and their salts and solvates, wherein B, R1, R2, R3, R3', R4, R4', and R5 are as set forth in the specification, as well as to methods for their preparation, pharmaceutical compositions comprising the same, and use thereof for the treatment and/or prevention of, e.g., MPS1, optionally in combination with α-L-iduronidase or an analog or variant thereof, e.g., laronidase.

Visible-light induced copper(i)-catalyzed oxidative cyclization of: O -aminobenzamides with methanol and ethanol via HAT

The use of the in situ generated ligand-copper superoxo complex absorbing light energy to activate the alpha C(sp3)-H of MeOH and EtOH via the hydrogen atom transfer (HAT) process for the synthesis of quinazolinones by oxidative cyclization of alcohols with o-aminobenzamide has been investigated. The synthetic utility of this protocol offers an efficient synthesis of a quinazolinone intermediate for erlotinb (anti-cancer agent) and 30 examples were reported.